News | July 02, 2021
Sandu Pharmaceuticals Q4FY21 PAT at Rs. 46.14 lakhs
The company has posted net profit of Rs.1.09 crores for the 12 months period ended March 31, 2021
The company has posted net profit of Rs.1.09 crores for the 12 months period ended March 31, 2021
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
Sun Pharma has committed Rs. 100 crores towards these initiatives
The company has reported total income of Rs.355.43 crores during FY 2020-21
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
The company has posted net profit of Rs.12.12 crores for the 12 months period ended March 31, 2021
According to IQVIA sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales of approximately US $1.6 billion
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
